Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March

CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in March:

GlobeNewsWire • Feb 23, 2026

Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026

CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, will report fourth quarter and full year 2025 financial results and corporate highlights after the U.S. financial markets close on Thursday, February 26, 2026.

GlobeNewsWire • Feb 19, 2026

Relay Therapeutics Insider Sells 21,000 Shares for $166,700 After 65% Run

Donald Bergstrom sold 21,581 shares over Jan. 27 and Jan. 28, 2026, generating a total value of approximately $166,700 at a weighted average price around $7.72 per share. This transaction reduced his direct holdings by 4.89%, leaving him with 420,047 directly held shares post-sale.

The Motley Fool • Feb 6, 2026

Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026

CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 10:30 a.m.

GlobeNewsWire • Feb 4, 2026

Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer

Designation supported by robust clinical  data from ReDiscover trial with 600mg BID fasted and 400mg BID fed doses of zovegalisib in combination with fulvestrant Initial Phase 1/2 data of zovegalisib + fulvestrant at the 400mg BID fed (Phase 3 dose) in CDK4/6-experienced patients to be presented at ESMO Targeted Anticancer Therapies Congress on March 16 CAMBRIDGE, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) to zovegalisib (RLY-2608) in combination with fulvestrant for the treatment of adults with PIK3CA mutant, hormone receptor positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally advanced or metastatic breast cancer following recurrence or progression on or after treatment with a CDK4/6 inhibitor.

GlobeNewsWire • Feb 3, 2026

Oppenheimer Upgrade Fuels Relay Therapeutics Rally On Zovegalisib Optimism

Relay Therapeutics is upgraded to Outperform with a $14 price target, driven by optimism for zovegalisib in PIK3CA-mutant HR+/HER2- metastatic breast cancer. Zovegalisib's mutant-selective PI3Kα inhibition offers a differentiated safety and efficacy profile versus broader PI3K inhibitors, targeting a large, underserved patient population. RLAY's $596M cash position funds operations into 2029, supporting ongoing pivotal Phase 3 and expansion studies across oncology and vascular malformations.

Seeking Alpha • Jan 28, 2026

Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025

Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L patients Subset analyses show broad activity in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer, regardless of prior fulvestrant or other SERD exposure, or ESR1 mutation status Phase 3 ReDiscover-2 trial in CDK4/6-experienced breast cancer ongoing CAMBRIDGE, Mass., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced a subset analysis of interim clinical data for zovegalisib (RLY-2608), the first known investigational allosteric, pan-mutant and isoform-selective inhibitor of PI3Kα.

GlobeNewsWire • Dec 12, 2025

Relay Therapeutics Stock Has Jumped 60% in a Year — And One Investor Just Bought Nearly 4 Million More Shares

New York City-based Commodore Capital increased its RLAY position by 3,650,000 shares in the third quarter. The transaction value represented 0.7% of Commodore's 13F AUM for the period.

The Motley Fool • Dec 3, 2025

Relay Therapeutics Director Sells $300,000 Worth of Shares. Here's Why Investors Shouldn't Panic.

Chief Corporate Development Officer Peter Rahmer sold more than 40,000 shares of Relay Therapeutics in October. The sale, worth about $300,000, was partially due to company policy regarding vested restricted stock units.

The Motley Fool • Dec 3, 2025

Relay Therapeutics, Inc. (RLAY) Presents at Jefferies London Healthcare Conference 2025 Transcript

Relay Therapeutics, Inc. ( RLAY ) Jefferies London Healthcare Conference 2025 November 19, 2025 6:30 AM EST Company Participants Sanjiv Patel - CEO, President & Director Peter Rahmer - Chief Corporate Development Officer Conference Call Participants Zaki Molvi - Jefferies LLC, Research Division Presentation Zaki Molvi Jefferies LLC, Research Division All right. Good morning, everyone.

Seeking Alpha • Nov 22, 2025